-
1
-
-
69949109911
-
Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: Global estimates
-
Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009;374:903-11
-
(2009)
Lancet
, vol.374
, pp. 903-911
-
-
Watt, J.P.1
Wolfson, L.J.2
O'Brien, K.L.3
-
2
-
-
77952224999
-
-
Accessed 20 August 2014
-
World Health Organization. Global Immunization Data. 2014. Available from: http://www.who. int/immunization/monitoring-surveillance/Global-Immunization-Data.pdf [Accessed 20 August 2014]
-
(2014)
Global Immunization Data
-
-
World Health Organization1
-
4
-
-
80555156134
-
Neisseria meningitidis: Biology, microbiology, and epidemiology
-
Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012;799:1-20
-
(2012)
Methods Mol Biol
, vol.799
, pp. 1-20
-
-
Rouphael, N.G.1
Stephens, D.S.2
-
5
-
-
67349267346
-
Global epidemiology of meningococcal disease
-
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl 2):B51-63
-
(2009)
Vaccine
, vol.27
, pp. B51-B63
-
-
Harrison, L.H.1
Trotter, C.L.2
Ramsay, M.E.3
-
6
-
-
85081860442
-
Meningococcal disease in countries of the African meningitis belt, 2012
-
Accessed 21 August 2014
-
World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs and future perspectives. 2013. Available from: http://www.who.int/wer/2013/wer8812.pdf [Accessed 21 August 2014]
-
(2013)
Emerging Needs and Future Perspectives
-
-
World Health Organization1
-
9
-
-
79954645991
-
Healthcare utilization and cost of pneumococcal disease in the United States
-
Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011;29:3398-412
-
(2011)
Vaccine
, vol.29
, pp. 3398-3412
-
-
Huang, S.S.1
Johnson, K.M.2
Ray, G.T.3
-
10
-
-
79952498476
-
Meningococcal glycoconjugate vaccines
-
Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011;7:170-82
-
(2011)
Hum Vaccin
, vol.7
, pp. 170-182
-
-
Gasparini, R.1
Panatto, D.2
-
11
-
-
33846071231
-
Conquering the meningococcus
-
Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31:3-14
-
(2007)
FEMS Microbiol Rev
, vol.31
, pp. 3-14
-
-
Stephens, D.S.1
-
12
-
-
0031954454
-
Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994
-
Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998;26:1159-64
-
(1998)
Clin Infect Dis
, vol.26
, pp. 1159-1164
-
-
Erickson, L.1
De Wals, P.2
-
13
-
-
27844551865
-
Prevention of meningococcal disease
-
Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 2005;72:2049-56
-
(2005)
Am Fam Physician
, vol.72
, pp. 2049-2056
-
-
Kimmel, S.R.1
-
14
-
-
84870863719
-
Glycoconjugate vaccines
-
Pace D. Glycoconjugate vaccines. Expert Opin Biol Ther 2013;13(1):11-33
-
(2013)
Expert Opin Biol Ther
, vol.13
, Issue.1
, pp. 11-33
-
-
Pace, D.1
-
15
-
-
84892730857
-
Effect of a serogroup A meningococcal conjugate vaccine (PsATT) on serogroup A meningococcal meningitis and carriage in Chad: A community study
-
Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsATT) on serogroup A meningococcal meningitis and carriage in Chad: a community study Lancet. 2014;383:40-7
-
(2014)
Lancet.
, vol.383
, pp. 40-47
-
-
Daugla, D.M.1
Gami, J.P.2
Gamougam, K.3
-
16
-
-
0029653518
-
Whole-genome random sequencing and assembly of Haemophilus influenzae Rd
-
Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995;269:496-512
-
(1995)
Science
, vol.269
, pp. 496-512
-
-
Fleischmann, R.D.1
Adams, M.D.2
White, O.3
-
18
-
-
77957346208
-
Global use of Haemophilus influenzae type b conjugate vaccine
-
Ojo LR, O'Loughlin RE, Cohen AL, et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 2010;28:7117-22
-
(2010)
Vaccine
, vol.28
, pp. 7117-7122
-
-
Ojo, L.R.1
O'Loughlin, R.E.2
Cohen, A.L.3
-
19
-
-
0025321343
-
Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine
-
Shapiro ED, Berg AT. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 1990;85:643-7
-
(1990)
Pediatrics
, vol.85
, pp. 643-647
-
-
Shapiro, E.D.1
Berg, A.T.2
-
20
-
-
84890047355
-
Invasive Haemophilus influenzae type b disease in England and Wales: Who is at risk after 2 decades of routine childhood vaccination?
-
Collins S, Ramsay M, Campbell H, et al. Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis 2013;57:1715-21
-
(2013)
Clin Infect Dis
, vol.57
, pp. 1715-1721
-
-
Collins, S.1
Ramsay, M.2
Campbell, H.3
-
21
-
-
77949327232
-
Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccines in Korean infants:A meta-analysis
-
Hyunju L, Seokyung H, Lee HJ, Kim KH. Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccines in Korean infants:a meta-analysis. J Korean Med Sci 2010;25(1):90-6
-
(2010)
J Korean Med Sci
, vol.25
, Issue.1
, pp. 90-96
-
-
Hyunju, L.1
Seokyung, H.2
Lee, H.J.3
Kim, K.H.4
-
22
-
-
33745322043
-
Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era
-
Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6
-
(1993)
JAMA
, vol.269
, pp. 221-226
-
-
Adams, W.G.1
Deaver, K.A.2
Cochi, S.L.3
-
24
-
-
84881473631
-
Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction
-
Georges S, Lepoutre A, Dabernat H, Levy-Bruhl D. Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction. Epidemiol Infect 2013;141:1787-96
-
(2013)
Epidemiol Infect
, vol.141
, pp. 1787-1796
-
-
Georges, S.1
Lepoutre, A.2
Dabernat, H.3
Levy-Bruhl, D.4
-
25
-
-
85081870420
-
-
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/EpidemiologicalData/ [Accessed 4 September 2014]
-
Public Health England. Haemophilus influenzae Epidemiological Data. Available from: http://webarchive. nationalarchives.gov.uk/20140714084352/http://www.hpa.org. uk/Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/EpidemiologicalData/[Accessed 4 September 2014]
-
Haemophilus Influenzae Epidemiological Data
-
-
Public Health England1
-
26
-
-
80355141578
-
Haemophilus influenzae infections in the H. Influenzae type b conjugate vaccine era
-
Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J Clin Microbiol 2011;49:3728-32
-
(2011)
J Clin Microbiol
, vol.49
, pp. 3728-3732
-
-
Agrawal, A.1
Murphy, T.F.2
-
27
-
-
0031457271
-
Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T
-
Heath PT, Bowen-Morris J, Griffiths D, et al. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997;77:488-92
-
(1997)
Arch Dis Child
, vol.77
, pp. 488-492
-
-
Heath, P.T.1
Bowen-Morris, J.2
Griffiths, D.3
-
28
-
-
67651087009
-
Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom
-
Ladhani S, Heath PT, Ramsay ME, et al. Long-term immunological follow-up of children with Haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis 2009;49:372-80
-
(2009)
Clin Infect Dis
, vol.49
, pp. 372-380
-
-
Ladhani, S.1
Heath, P.T.2
Ramsay, M.E.3
-
29
-
-
84856698739
-
Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom
-
Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther 2012;34:385-99
-
(2012)
Clin Ther
, vol.34
, pp. 385-399
-
-
Ladhani, S.N.1
-
30
-
-
0038752646
-
Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis
-
McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003;361:1521-3
-
(2003)
Lancet
, vol.361
, pp. 1521-1523
-
-
McVernon, J.1
Andrews, N.2
Slack, M.P.3
Ramsay, M.E.4
-
31
-
-
59649101899
-
Invasive Haemophilus influenzae type B disease in five young children-Minnesota, 2008
-
Centers for Disease Control and Prevention. Invasive Haemophilus influenzae Type B disease in five young children-Minnesota, 2008. MMWR Morb Mortal Wkly Rep 2009;58(3):58-60
-
(2009)
MMWR Morb Mortal Wkly Rep
, vol.58
, Issue.3
, pp. 58-60
-
-
Centers for Disease Control and Prevention1
-
32
-
-
4644253794
-
Trends in Haemophilus influenzae type b infections in adults in England and Wales: Surveillance study
-
McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004;329:655-8
-
(2004)
BMJ
, vol.329
, pp. 655-658
-
-
McVernon, J.1
Trotter, C.L.2
Slack, M.P.3
Ramsay, M.E.4
-
33
-
-
0020056871
-
Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B
-
Insel RA, Anderson PW. Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J Immunol 1982;128:1267-70
-
(1982)
J Immunol
, vol.128
, pp. 1267-1270
-
-
Insel, R.A.1
Anderson, P.W.2
-
34
-
-
84860319956
-
Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era
-
Nix EB, Hawdon N, Gravelle S, et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin Vaccine Immunol 2012;19:766-71
-
(2012)
Clin Vaccine Immunol
, vol.19
, pp. 766-771
-
-
Nix, E.B.1
Hawdon, N.2
Gravelle, S.3
-
35
-
-
77952584729
-
Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: Evidence for herd effects and strain replacement due to Hib vaccination
-
Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010;28:4073-8
-
(2010)
Vaccine
, vol.28
, pp. 4073-4078
-
-
Adam, H.J.1
Richardson, S.E.2
Jamieson, F.B.3
-
36
-
-
84880913322
-
Identification of Haemophilus influenzae clones associated with invasive disease a decade after introduction of H. Influenzae serotype b vaccination in Italy
-
Giufrè M, Cardines R, Accogli M, et al. Identification of Haemophilus influenzae clones associated with invasive disease a decade after introduction of H. influenzae serotype b vaccination in Italy. Clin Vaccine Immunol 2013;20:1223-9
-
(2013)
Clin Vaccine Immunol
, vol.20
, pp. 1223-1229
-
-
Giufrè, M.1
Cardines, R.2
Accogli, M.3
-
37
-
-
77649108075
-
Invasive Haemophilus influenzae Disease, Europe, 1996-2006
-
Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae Disease, Europe, 1996-2006. Emerg Infect Dis 2010;16:455-63
-
(2010)
Emerg Infect Dis
, vol.16
, pp. 455-463
-
-
Ladhani, S.1
Slack, M.P.2
Heath, P.T.3
-
38
-
-
84878001032
-
Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011
-
Bruce MG, Zulz T, DeByle C, et al. Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011. Emerg Infect Dis 2013;19:932-7
-
(2013)
Emerg Infect Dis
, vol.19
, pp. 932-937
-
-
Bruce, M.G.1
Zulz, T.2
DeByle, C.3
-
39
-
-
85081862540
-
-
[Accessed 3 July 2014]
-
GAVI Alliance. Hib Initiative: a GAVI success story. 2011. Available from: http://www.gavi.org/library/news/roi/2010/hib-initiative--a-gavi-success-story/[Accessed 3 July 2014]
-
(2011)
Hib Initiative: A GAVI Success Story
-
-
Alliance, G.A.V.I.1
-
40
-
-
84879234449
-
Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: Regional analysis and assessment of major determinants
-
e9
-
Griffiths UK, Clark A, Hajjeh R. Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants. J Pediatr 2013;163:S50-S9.e9
-
(2013)
J Pediatr
, vol.163
, pp. S50-S59
-
-
Griffiths, U.K.1
Clark, A.2
Hajjeh, R.3
-
41
-
-
3242797283
-
A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b
-
Vérez-Bencomo V, Fernández-Santana V, Ardí E, et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004;35:522
-
(2004)
Science
, vol.35
, pp. 522
-
-
Vérez-Bencomo, V.1
Fernández-Santana, V.2
Ardí, E.3
-
42
-
-
33749488093
-
Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against haemophilus influenzae type b in human adult volunteers
-
Torano G, Toledo ME, Baly A, et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against haemophilus influenzae type b in human adult volunteers. Clin Vaccine Immunol 2006;13(9):1052-6
-
(2006)
Clin Vaccine Immunol
, vol.13
, Issue.9
, pp. 1052-1056
-
-
Torano, G.1
Toledo, M.E.2
Baly, A.3
-
43
-
-
84858769574
-
Evaluation of Haemophilus influenzae type b vaccine for routine immunization in Nepali infants
-
Metz JA, Hanieh S, Pradhan R, et al. Evaluation of Haemophilus influenzae type b vaccine for routine immunization in Nepali infants. Pediatr Infect Dis J 2012;31:e66-72
-
(2012)
Pediatr Infect Dis J
, vol.31
, pp. e66-e72
-
-
Metz, J.A.1
Hanieh, S.2
Pradhan, R.3
-
44
-
-
77953141751
-
The Elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal
-
Cissé MF, Breugelmans JG, Bâ M, et al. The Elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 2010;29:499-503
-
(2010)
Pediatr Infect Dis J
, vol.29
, pp. 499-503
-
-
Cissé, M.F.1
Breugelmans, J.G.2
Bâ, M.3
-
45
-
-
84879247307
-
Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India
-
Clark AD, Griffiths UK, Abbas SS, et al. Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India. J Pediatr 2013;163:S60-72
-
(2013)
J Pediatr
, vol.163
, pp. S60-S72
-
-
Clark, A.D.1
Griffiths, U.K.2
Abbas, S.S.3
-
46
-
-
22244476078
-
Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: A prospective study
-
Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005;366:144-50
-
(2005)
Lancet
, vol.366
, pp. 144-150
-
-
Adegbola, R.A.1
Secka, O.2
Lahai, G.3
-
47
-
-
84879197428
-
Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization
-
Oluwalana C, Howie SR, Secka O, et al. Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. J Pediatr 2013;163:S4-7
-
(2013)
J Pediatr
, vol.163
, pp. S4-S7
-
-
Oluwalana, C.1
Howie, S.R.2
Secka, O.3
-
48
-
-
78649338859
-
Haemophilus influenzae type b conjugate vaccines: Considerations for vaccination schedules and implications for developing countries
-
Fitzwater SP, Watt JP, Levine OS, Santosham M. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Hum Vaccin 2010;6:810-18
-
(2010)
Hum Vaccin
, vol.6
, pp. 810-818
-
-
Fitzwater, S.P.1
Watt, J.P.2
Levine, O.S.3
Santosham, M.4
-
50
-
-
82455162581
-
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model
-
Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011;29:8870-6
-
(2011)
Vaccine
, vol.29
, pp. 8870-8876
-
-
Skinner, J.M.1
Indrawati, L.2
Cannon, J.3
-
51
-
-
0033375209
-
A brief history of pneumococcal vaccines
-
Suppl 1
-
Austrian R. A brief history of pneumococcal vaccines. Drugs Aging 1999;15(Suppl 1):1-10
-
(1999)
Drugs Aging
, vol.15
, pp. 1-10
-
-
Austrian, R.1
-
52
-
-
84861480714
-
Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period
-
De Serres G, Pilishvili T, Link-Gelles R, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 2012;30:4067-72
-
(2012)
Vaccine
, vol.30
, pp. 4067-4072
-
-
De Serres, G.1
Pilishvili, T.2
Link-Gelles, R.3
-
53
-
-
71949103062
-
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
-
Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41
-
(2010)
J Infect Dis
, vol.201
, pp. 32-41
-
-
Pilishvili, T.1
Lexau, C.2
Farley, M.M.3
-
54
-
-
84882573112
-
Invasive Pneumococcal disease (IPD) in England and Wales after 7 -valent conjugate vaccine (PCV7); potential impact of 10 and 13 valent vaccines
-
Presented at the, 9 - 13 June, Brussels, Belgium
-
Kaye P, Malkani R, Martin S, et al. Invasive Pneumococcal Disease (IPD) in England and Wales after 7 -valent conjugate vaccine (PCV7); Potential impact of 10 and 13 valent vaccines. Presented at the 27th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). 9 - 13 June 2009; Brussels, Belgium
-
(2009)
27th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID)
-
-
Kaye, P.1
Malkani, R.2
Martin, S.3
-
55
-
-
56349119400
-
The effect of vaccination on Streptococcus pneumoniae resistance
-
Leibovitz E. The effect of vaccination on Streptococcus pneumoniae resistance. Curr Infect Dis Rep 2008;10:182-91
-
(2008)
Curr Infect Dis Rep
, vol.10
, pp. 182-191
-
-
Leibovitz, E.1
-
58
-
-
84906679124
-
Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: Findings from cross-sectional carriage studies
-
Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2014;2:e397-405
-
(2014)
Lancet Glob Health
, vol.2
, pp. e397-e405
-
-
Hammitt, L.L.1
Akech, D.O.2
Morpeth, S.C.3
-
59
-
-
84884504627
-
Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes
-
Grant L, Burbidge P, Haston M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One 2013;8(9):e74906
-
(2013)
PLoS One
, vol.8
, Issue.9
-
-
Grant, L.1
Burbidge, P.2
Haston, M.3
-
60
-
-
26944441984
-
Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae
-
Bieging KT, Rajam G, Holder P, et al. Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin Diagn Lab Immunol 2005;12:1238-42
-
(2005)
Clin Diagn Lab Immunol
, vol.12
, pp. 1238-1242
-
-
Bieging, K.T.1
Rajam, G.2
Holder, P.3
-
61
-
-
65549115895
-
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine
-
Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28:S66-76
-
(2009)
Pediatr Infect Dis J
, vol.28
, pp. S66-S76
-
-
Vesikari, T.1
Wysocki, J.2
Chevallier, B.3
-
62
-
-
77649156773
-
Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
-
Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4
-
(2010)
BMC Pediatr
, vol.10
, pp. 4
-
-
Hausdorff, W.P.1
Hoet, B.2
Schuerman, L.3
-
63
-
-
84903304920
-
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial
-
Tregnaghi MW, Saéz-Llorens X, López P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014;11:e1001657
-
(2014)
PLoS Med
, vol.11
-
-
Tregnaghi, M.W.1
Saéz-Llorens, X.2
López, P.3
-
64
-
-
85099173020
-
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiDCV10) against invasive pneumococcal disease: A cluster randomised trial
-
Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiDCV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381:214-22
-
(2013)
Lancet
, vol.381
, pp. 214-222
-
-
Palmu, A.A.1
Jokinen, J.2
Borys, D.3
-
65
-
-
33644645379
-
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypable Haemophilus influenzae: A randomised double-blind efficacy study
-
Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8
-
(2006)
Lancet
, vol.367
, pp. 740-748
-
-
Prymula, R.1
Peeters, P.2
Chrobok, V.3
-
66
-
-
70649103013
-
Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. Influenzae in children under 2 years of age
-
Prymula R, Kriz P, Kaliskova E, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009;28:71-8
-
(2009)
Vaccine
, vol.28
, pp. 71-78
-
-
Prymula, R.1
Kriz, P.2
Kaliskova, E.3
-
69
-
-
77956295617
-
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers
-
Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010;126:e493-505
-
(2010)
Pediatrics
, vol.126
, pp. e493-e505
-
-
Yeh, S.H.1
Gurtman, A.2
Hurley, D.C.3
-
70
-
-
77953156443
-
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers
-
Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010;17:1017-26
-
(2010)
Clin Vaccine Immunol
, vol.17
, pp. 1017-1026
-
-
Esposito, S.1
Tansey, S.2
Thompson, A.3
-
71
-
-
77951875521
-
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine
-
Bryant KA, Block SL, Baker SA, Group PCVIS. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010;125:866-75
-
(2010)
Pediatrics
, vol.125
, pp. 866-875
-
-
Bryant, K.A.1
Block, S.L.2
Baker, S.A.3
Group, P.C.V.I.S.4
-
72
-
-
77952584765
-
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany
-
Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28:4192-203
-
(2010)
Vaccine
, vol.28
, pp. 4192-4203
-
-
Kieninger, D.M.1
Kueper, K.2
Steul, K.3
-
73
-
-
84890085799
-
Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012
-
Demczuk WH, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013;59:778-88
-
(2013)
Can J Microbiol
, vol.59
, pp. 778-788
-
-
Demczuk, W.H.1
Martin, I.2
Griffith, A.3
-
74
-
-
85081860905
-
-
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/BackgroundEpidemiologyPneumococcal/IPDGraphs/pneumoNumberLab-ConfirmedAgeSpecific/[Accessed 13 August 2014]
-
Public Health England. Numbers of laboratory confirmed invasive pneumococcal disease cases by age group, in England and Wales, 1996-2005. 2008. Available from: http://webarchive. nationalarchives.gov.uk/20140714084352/http://www.hpa.org. uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/BackgroundEpidemiologyPneumococcal/IPDGraphs/pneumoNumberLab-ConfirmedAgeSpecific/[Accessed 13 August 2014]
-
(2008)
Numbers of Laboratory Confirmed Invasive Pneumococcal Disease Cases by Age Group, in England and Wales, 1996-2005
-
-
Public Health England1
-
75
-
-
78651230835
-
13-valent pneumococcal conjugate vaccine
-
9
-
13-valent pneumococcal conjugate vaccine. Prescrire Int 2011;20(112):5-7; 9
-
(2011)
Prescrire Int
, vol.20
, Issue.112
, pp. 5-7
-
-
-
76
-
-
84885952880
-
Safety of 13-valent pneumococcal conjugate vaccine in infants and children: Meta-analysis of 13 clinical trials in 9 countries
-
Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine 2013;31:5289-95
-
(2013)
Vaccine
, vol.31
, pp. 5289-5295
-
-
Thompson, A.1
Gurtman, A.2
Patterson, S.3
-
77
-
-
84896543826
-
Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?
-
Weil-Olivier C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine 2014;32:2022-6
-
(2014)
Vaccine
, vol.32
, pp. 2022-2026
-
-
Weil-Olivier, C.1
Gaillat, J.2
-
78
-
-
84898449980
-
Pneumococcal vaccination strategies in adult population: Perspectives with the pneumococcal 13 -valent polysaccharide conjugate vaccine
-
Alicino C, Barberis I, Orsi A, Durando P. Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 -valent polysaccharide conjugate vaccine. Minerva Med 2014;105:89-97
-
(2014)
Minerva Med
, vol.105
, pp. 89-97
-
-
Alicino, C.1
Barberis, I.2
Orsi, A.3
Durando, P.4
-
79
-
-
84880722937
-
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
-
Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31:3577-84
-
(2013)
Vaccine
, vol.31
, pp. 3577-3584
-
-
Jackson, L.A.1
Gurtman, A.2
Van Cleeff, M.3
-
80
-
-
85081871825
-
-
Accessed 5 September 2014
-
FDA. PREVNAR 13 VRBPAC Adult Indication Briefing Document. 2011. Available from: http://www.fda. gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf [Accessed 5 September 2014]
-
(2011)
PREVNAR 13 VRBPAC Adult Indication Briefing Document
-
-
FDA1
-
81
-
-
0035804857
-
Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era
-
Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-35
-
(2001)
JAMA
, vol.285
, pp. 1729-1735
-
-
Robinson, K.A.1
Baughman, W.2
Rothrock, G.3
-
82
-
-
67651097472
-
Invasive pneumococcal disease among adults: Associations among serotypes, disease characteristics, and outcome
-
Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009;49:e23-9
-
(2009)
Clin Infect Dis
, vol.49
, pp. e23-e29
-
-
Jansen, A.G.1
Rodenburg, G.D.2
Van Der Ende, A.3
-
83
-
-
84884220307
-
Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years
-
Mitchell R, Trück J, Pollard AJ. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. Expert Opin Biol Ther 2013;13:1451-65
-
(2013)
Expert Opin Biol Ther
, vol.13
, pp. 1451-1465
-
-
Mitchell, R.1
Trück, J.2
Pollard, A.J.3
-
84
-
-
84892955220
-
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine
-
Frenck R, Thompson A, Senders S, et al. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014;33:183-9
-
(2014)
Pediatr Infect Dis J
, vol.33
, pp. 183-189
-
-
Frenck, R.1
Thompson, A.2
Senders, S.3
-
85
-
-
78650215295
-
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine -recommendations of the Advisory Committee on Immunization Practices (ACIP)
-
Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine -recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59:1-18
-
(2010)
MMWR Recomm Rep
, vol.59
, pp. 1-18
-
-
Centers for Disease Control and Prevention (CDC)1
Nuorti, J.P.2
Whitney, C.G.3
-
86
-
-
84861481752
-
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
-
van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24
-
(2012)
J Infect
, vol.65
, pp. 17-24
-
-
Van Hoek, A.J.1
Andrews, N.2
Waight, P.A.3
-
88
-
-
84896544594
-
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18-49 years, naïve to 23-valent pneumococcal polysaccharide vaccine
-
Presented at the, 27 - 30th April, Berlin
-
Bryant K, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18-49 years, naïve to 23-valent pneumococcal polysaccharide vaccine. Presented at the 23rd ECCMID (European Society of Clinical Microbiology and Infectious Diseases). 27 -- 30th April 2013; Berlin
-
(2013)
23rd ECCMID (European Society of Clinical Microbiology and Infectious Diseases)
-
-
Bryant, K.1
Frenck, R.2
Gurtman, A.3
-
89
-
-
77949332316
-
Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: Impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines
-
Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010;14:e197-209
-
(2010)
Int J Infect Dis
, vol.14
, pp. e197-e209
-
-
Isaacman, D.J.1
McIntosh, E.D.2
Reinert, R.R.3
-
90
-
-
84873262171
-
Imöhl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children
-
van der Linden M, Reinert RR, Kern WV, Imöhl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis 2013;13:70
-
(2013)
BMC Infect Dis
, vol.13
, pp. 70
-
-
Van Der Linden, M.1
Reinert, R.R.2
Kern, W.V.3
-
91
-
-
84862198729
-
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
-
Earnshaw SR, McDade CL, Zanotti G, et al. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis 2012;12:101
-
(2012)
BMC Infect Dis
, vol.12
, pp. 101
-
-
Earnshaw, S.R.1
McDade, C.L.2
Zanotti, G.3
-
92
-
-
84883169333
-
A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries
-
Martí SG, Colantonio L, Bardach A, et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc 2013;11:21
-
(2013)
Cost Eff Resour Alloc
, vol.11
, pp. 21
-
-
Martí, S.G.1
Colantonio, L.2
Bardach, A.3
-
93
-
-
78650497300
-
Global prevailing and emerging pediatric pneumococcal serotypes
-
McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011;10:109-29.
-
(2011)
Expert Rev Vaccines
, vol.10
, pp. 109-129
-
-
McIntosh, E.D.1
Reinert, R.R.2
-
94
-
-
80051938182
-
New conjugate vaccines for the prevention of pneumococcal disease in developing countries
-
Ginsburg AS, Alderson MR. New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today 2011;47(3):207-14
-
(2011)
Drugs Today
, vol.47
, Issue.3
, pp. 207-214
-
-
Ginsburg, A.S.1
Alderson, M.R.2
-
95
-
-
34249930262
-
Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP
-
Cao J, Chen D, Xu W, et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 2007;25:4996-5005
-
(2007)
Vaccine
, vol.25
, pp. 4996-5005
-
-
Cao, J.1
Chen, D.2
Xu, W.3
-
96
-
-
61849117441
-
Caseinolytic protease: A protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection
-
Cao J, Li D, Gong Y, et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol 2009;156:52-60.
-
(2009)
Clin Exp Immunol
, vol.156
, pp. 52-60
-
-
Cao, J.1
Li, D.2
Gong, Y.3
-
97
-
-
84899994434
-
Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial
-
Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine 2014;32:3025-34.
-
(2014)
Vaccine
, vol.32
, pp. 3025-3034
-
-
Prymula, R.1
Pazdiora, P.2
Traskine, M.3
-
98
-
-
78149387943
-
Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project
-
Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7
-
(2010)
PLoS Med
, pp. 7
-
-
Johnson, H.L.1
Deloria-Knoll, M.2
Levine, O.S.3
-
99
-
-
79953132642
-
The African vaccine-preventable diseases network: A vaccine advocacy initiative
-
Wiysonge CS, Armah GE, Madhi SA, et al. The African Vaccine-Preventable Diseases Network: a vaccine advocacy initiative. Pan Afr Med J 2011;8:24
-
(2011)
Pan Afr Med J
, vol.8
, pp. 24
-
-
Wiysonge, C.S.1
Armah, G.E.2
Madhi, S.A.3
-
100
-
-
67349129949
-
-
Accessed 4 September 2014
-
UNICEF/WHO. Expanding immunization coverage. 2011. Available from: http://www.unicef.org/immunization/index-coverage.html [Accessed 4 September 2014]
-
(2011)
Expanding Immunization Coverage
-
-
UNICEF/WHO1
-
102
-
-
84873255900
-
-
Accessed 3 July 2014
-
HealthyPeople.gov. Immunization and Infectious Diseases. 2014. Available from: http://www. healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=23 [Accessed 3 July 2014]
-
(2014)
Immunization and Infectious Diseases
-
-
-
103
-
-
84888098943
-
Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X
-
Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA 2013;110:19077-82
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 19077-19082
-
-
Micoli, F.1
Romano, M.R.2
Tontini, M.3
-
104
-
-
84883598147
-
Effectiveness of meningococcal serogroup C vaccine programmes
-
Borrow R, Abad R, Trotter C, et al. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 2013;31:4477-86.
-
(2013)
Vaccine
, vol.31
, pp. 4477-4486
-
-
Borrow, R.1
Abad, R.2
Trotter, C.3
-
105
-
-
84874708395
-
The changing epidemiology of meningococcal disease in North America 1945-2010
-
Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother 2013;9:162-71
-
(2013)
Hum Vaccin Immunother
, vol.9
, pp. 162-171
-
-
Baccarini, C.1
Ternouth, A.2
Wieffer, H.3
Vyse, A.4
-
108
-
-
0035888124
-
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story
-
Suppl 1
-
Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-67
-
(2001)
Vaccine
, vol.20
, pp. S58-S67
-
-
Miller, E.1
Salisbury, D.2
Ramsay, M.3
-
109
-
-
0035915614
-
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
-
Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195-6
-
(2001)
Lancet
, vol.357
, pp. 195-196
-
-
Ramsay, M.E.1
Andrews, N.2
Kaczmarski, E.B.3
Miller, E.4
-
111
-
-
3242768475
-
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
-
Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7
-
(2004)
Lancet
, vol.364
, pp. 365-367
-
-
Trotter, C.L.1
Andrews, N.J.2
Kaczmarski, E.B.3
-
112
-
-
20444437173
-
Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain
-
Larrauri A, Cano R, Garciá M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005;23:4097-100
-
(2005)
Vaccine
, vol.23
, pp. 4097-4100
-
-
Larrauri, A.1
Cano, R.2
Garciá, M.3
Mateo, S.4
-
113
-
-
33746653839
-
Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules
-
Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill 2006;11:E060302.4
-
(2006)
Euro Surveill
, vol.11
-
-
Cameron, C.1
Pebody, R.2
-
114
-
-
77952004260
-
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
-
Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-7
-
(2010)
Clin Vaccine Immunol
, vol.17
, pp. 840-847
-
-
Campbell, H.1
Andrews, N.2
Borrow, R.3
-
115
-
-
84861526415
-
Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom
-
Findlow H, Borrow R, Andrews N, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. Pediatr Infect Dis J 2012;31:616-22
-
(2012)
Pediatr Infect Dis J
, vol.31
, pp. 616-622
-
-
Findlow, H.1
Borrow, R.2
Andrews, N.3
-
116
-
-
33751555760
-
Serogroup C meningococcal glycoconjugate vaccine in adolescents: Persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
-
Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006;43:1387-94.
-
(2006)
Clin Infect Dis
, vol.43
, pp. 1387-1394
-
-
Snape, M.D.1
Kelly, D.F.2
Salt, P.3
-
117
-
-
0036677184
-
Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children
-
McVernon J, Maclennan J, Buttery J, et al. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002;21:747-53
-
(2002)
Pediatr Infect Dis J
, vol.21
, pp. 747-753
-
-
McVernon, J.1
Maclennan, J.2
Buttery, J.3
-
118
-
-
47149093375
-
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: Observational study
-
Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91
-
(2008)
BMJ
, vol.336
, pp. 1487-1491
-
-
Snape, M.D.1
Kelly, D.F.2
Lewis, S.3
-
119
-
-
77952993552
-
Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: A phase 4 clinical trial
-
Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010;50(12):1601-10
-
(2010)
Clin Infect Dis
, vol.50
, Issue.12
, pp. 1601-1610
-
-
Perrett, K.P.1
Winter, A.P.2
Kibwana, E.3
-
121
-
-
84883133746
-
Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
-
de Whalley PC, Snape MD, Plested E, et al. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child 2013;98:686-91
-
(2013)
Arch Dis Child
, vol.98
, pp. 686-691
-
-
De Whalley, P.C.1
Snape, M.D.2
Plested, E.3
-
122
-
-
84903515497
-
Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers
-
Stoof SP, van der Klis FR, van Rooijen DM, et al. Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers. PLoS One 2014;9:e100651
-
(2014)
PLoS One
, vol.9
-
-
Stoof, S.P.1
Van Der Klis, F.R.2
Van Rooijen, D.M.3
-
125
-
-
83155176172
-
Meningococcal conjugate vaccines policy update: Booster dose recommendations
-
Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics 2011;128(6):1213-18
-
(2011)
Pediatrics
, vol.128
, Issue.6
, pp. 1213-1218
-
-
Committee on Infectious Diseases1
-
127
-
-
0031552196
-
Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales
-
Ramsay M, Kaczmarski E, Rush M, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997;7:R49-54
-
(1997)
Commun Dis Rep CDR Rev
, vol.7
, pp. R49-R54
-
-
Ramsay, M.1
Kaczmarski, E.2
Rush, M.3
-
128
-
-
40549089883
-
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
-
Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43
-
(2008)
J Infect Dis
, vol.197
, pp. 737-743
-
-
Maiden, M.C.1
Ibarz-Pavón, A.B.2
Urwin, R.3
-
129
-
-
73649112805
-
Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: Implications for prevention of meningococcal disease
-
Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184-91.
-
(2010)
Clin Infect Dis
, vol.50
, pp. 184-191
-
-
Cohn, A.C.1
MacNeil, J.R.2
Harrison, L.H.3
-
131
-
-
79957886417
-
Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants
-
Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011;127:e1375-85.
-
(2011)
Pediatrics
, vol.127
, pp. e1375-e1385
-
-
Bryant, K.A.1
Marshall, G.S.2
Marchant, C.D.3
-
132
-
-
74049124340
-
Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants
-
Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010;29:48-52.
-
(2010)
Pediatr Infect Dis J
, vol.29
, pp. 48-52
-
-
Marchant, C.D.1
Miller, J.M.2
Marshall, G.S.3
-
133
-
-
77952118055
-
-
Accessed 17 November 2014
-
Nimenrix. Summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/26514 [Accessed 17 November 2014]
-
Summary of Product Characteristics
-
-
Nimenrix1
-
134
-
-
79956193785
-
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-monthold children
-
Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-monthold children. Vaccine 2011;29:4264-73.
-
(2011)
Vaccine
, vol.29
, pp. 4264-4273
-
-
Knuf, M.1
Pantazi-Chatzikonstantinou, A.2
Pfletschinger, U.3
-
135
-
-
84874465958
-
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: Results of an open, randomised, controlled study
-
Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis 2013;13:116
-
(2013)
BMC Infect Dis
, vol.13
, pp. 116
-
-
Borja-Tabora, C.1
Montalban, C.2
Memish, Z.A.3
-
136
-
-
84876665145
-
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2- 10-year-old children: Results of an open, randomised, controlled study
-
Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2- 10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr 2013;172:601-12
-
(2013)
Eur J Pediatr
, vol.172
, pp. 601-612
-
-
Knuf, M.1
Romain, O.2
Kindler, K.3
-
137
-
-
84874494263
-
Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)
-
Østergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis 2013;17:e173-6.
-
(2013)
Int J Infect Dis
, vol.17
, pp. e173-e176
-
-
Østergaard, L.1
Van Der Wielen, M.2
Bianco, V.3
Miller, J.M.4
-
138
-
-
84898483961
-
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: A new conjugate vaccine against invasive meningococcal disease
-
Hedari C, Khinkarly RW, Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist 2014;7:85-99
-
(2014)
Infect Drug Resist
, vol.7
, pp. 85-99
-
-
Hedari, C.1
Khinkarly, R.W.2
Dbaibo, G.S.3
-
139
-
-
84872282456
-
Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity
-
Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013;56:354-63
-
(2013)
Clin Infect Dis
, vol.56
, pp. 354-363
-
-
Kristiansen, P.A.1
Diomandé, F.2
Ba, A.K.3
-
140
-
-
84880934608
-
Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine
-
Kristiansen PA, Ba AK, Sanou I, et al. Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infect Dis 2013;13:363
-
(2013)
BMC Infect Dis
, vol.13
, pp. 363
-
-
Kristiansen, P.A.1
Ba, A.K.2
Sanou, I.3
-
141
-
-
79959305905
-
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans
-
Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364:2293-304
-
(2011)
N Engl J Med
, vol.364
, pp. 2293-2304
-
-
Sow, S.O.1
Okoko, B.J.2
Diallo, A.3
-
142
-
-
84896726517
-
Benefits of using vaccines out of the cold chain: Delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin
-
Zipursky S, Djingarey MH, Lodjo JC, et al. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 2014;32:1431-5.
-
(2014)
Vaccine
, vol.32
, pp. 1431-1435
-
-
Zipursky, S.1
Djingarey, M.H.2
Lodjo, J.C.3
-
144
-
-
84889032744
-
Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination
-
Collard JM, Issaka B, Zaneidou M, et al. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis 2013;13:576
-
(2013)
BMC Infect Dis
, vol.13
, pp. 576
-
-
Collard, J.M.1
Issaka, B.2
Zaneidou, M.3
-
145
-
-
0035196375
-
Clonal expansion of sequence type (ST-) 5 and emergence of ST-7 in serogroup A meningococci, Africa
-
Nicolas P, Décousset L, Riglet V, et al. Clonal expansion of sequence type (ST-) 5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001;7:849-54
-
(2001)
Emerg Infect Dis
, vol.7
, pp. 849-854
-
-
Nicolas, P.1
Décousset, L.2
Riglet, V.3
-
146
-
-
26944439440
-
Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes
-
Nicolas P, Norheim G, Garnotel E, et al. Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005;43:5129-35
-
(2005)
J Clin Microbiol
, vol.43
, pp. 5129-5135
-
-
Nicolas, P.1
Norheim, G.2
Garnotel, E.3
-
147
-
-
79956323880
-
Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso
-
Article describing the epidemic potential of meningococcal serogroup X.
-
Delrieu I, Yaro S, Tamekloé TA, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011;6:e19513 . Article describing the epidemic potential of meningococcal serogroup X.
-
(2011)
PLoS One
, vol.6
-
-
Delrieu, I.1
Yaro, S.2
Tamekloé, T.A.3
-
149
-
-
84903304241
-
Improving access to vaccines through tiered pricing
-
Berkley S. Improving access to vaccines through tiered pricing. Lancet 2014;383:2265-7
-
(2014)
Lancet
, vol.383
, pp. 2265-2267
-
-
Berkley, S.1
-
150
-
-
85081862485
-
-
Accessed 30 August 2014
-
UNICEF. Ukraine Statistics. 2013. Available from: http://www.unicef. org/infobycountry/ukraine-statistics.html [Accessed 30 August 2014]
-
(2013)
Ukraine Statistics
-
-
UNICEF1
-
151
-
-
85081865921
-
-
Accessed 4 September 2014
-
UNICEF. Egypt Statistics. 2013. Available from: http://www.unicef. org/infobycountry/egypt-statistics.html [Accessed 4 September 2014]
-
(2013)
Egypt Statistics
-
-
UNICEF1
-
152
-
-
85081870951
-
-
Accessed 4 September 2014
-
UNICEF. Syria Statistics. 2013. Available from: http://www.unicef. org/infobycountry/syria-statistics.html [Accessed 4 September 2014]
-
(2013)
Syria Statistics
-
-
UNICEF1
-
154
-
-
85081863887
-
-
Accessed 4 September 2014
-
The Lancet Infectious Diseases. A wakeup call for polio eradication 2014. Available from: http://www.thelancet. com/journals/laninf/article/PIIS1473-3099(13)70368-2/fulltext%3Felsca1%3DETOC-TLID%26elsca2%3Demail%26elsca3%3DHTDJ [Accessed 4 September 2014]
-
(2014)
A Wakeup Call for Polio Eradication
-
-
The Lancet Infectious Diseases1
-
155
-
-
84878995680
-
CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens
-
Sharma SK, Roumanes D, Almudevar A, et al. CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine 2013;31:3090-7
-
(2013)
Vaccine
, vol.31
, pp. 3090-3097
-
-
Sharma, S.K.1
Roumanes, D.2
Almudevar, A.3
-
156
-
-
33645532223
-
Pneumococcal vaccine-direct and indirect ("herd") effects
-
Musher DM. Pneumococcal vaccine--direct and indirect ("herd") effects. N Engl J Med 2006;354:1522-4
-
(2006)
N Engl J Med
, vol.354
, pp. 1522-1524
-
-
Musher, D.M.1
-
157
-
-
34547948567
-
Capsule switching and capsule replacement in vaccine-preventable bacterial diseases
-
Tsang R. Capsule switching and capsule replacement in vaccine-preventable bacterial diseases. Lancet Infect Dis 2007;7:569-70
-
(2007)
Lancet Infect Dis
, vol.7
, pp. 569-570
-
-
Tsang, R.1
-
158
-
-
33748883185
-
No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales
-
author reply 7-8
-
Trotter CL, Ramsay ME, Gray S, et al. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006;6:616-17; author reply 7-8
-
(2006)
Lancet Infect Dis
, vol.6
, pp. 616-617
-
-
Trotter, C.L.1
Ramsay, M.E.2
Gray, S.3
-
159
-
-
20844442319
-
Capsules, clones, and curious events: Pneumococcus under fire from polysaccharide conjugate vaccine
-
Long SS. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005;41:30-4
-
(2005)
Clin Infect Dis
, vol.41
, pp. 30-34
-
-
Long, S.S.1
-
160
-
-
84889680691
-
Advances towards the prevention of meningococcal B disease: A multidimensional story
-
Suppl 1
-
Roderick M, Finn A. Advances towards the prevention of meningococcal B disease: a multidimensional story. J Infect 2014;68(Suppl 1):S76-82
-
(2014)
J Infect
, vol.68
, pp. S76-S82
-
-
Roderick, M.1
Finn, A.2
-
161
-
-
33845600413
-
WHO vaccine-preventable diseases: Monitoring system
-
Accessed 4 September 2014
-
World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2014 global summary. 2014. Available from: http://apps.who. int/immunization-monitoring/globalsummary [Accessed 4 September 2014]
-
(2014)
2014 Global Summary
-
-
World Health Organization1
|